Gainers

Prothena Corporation plc (NASDAQ:PRTA) shares climbed 76.4% to $54.54 after Biogen and Eisai Co. Ltd. announced late Tuesday positive results from a late-stage study of their Alzheimer's treatment candidate. Prothena is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative diseases, like Alzheimer's. Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares gained 72.1% to $8.09 after Biogen and Eisai announced their Phase 3 Clarity study of lecanemab met its primary endpoint. PepGen Inc. (NASDAQ:PEPG) gained 70% to $8.86 after the company announced results from its Phase 1 healthy...